• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Hacking The Nervous System
(Photo: © Job Boot) One nerve connects your vital organs, sensing and shaping your health. If we learn to control it, the future of medicine will be electric.When Maria Vrind, a former gymnast from Volendam in the Netherlands, found that the only way she could put her socks on in the morning was to lie on her back with her feet in the air, she had to accept that things had reached a crisis point. “I had become so stiff I couldn’t stand up,” she says. “It was a great shock because I’m such an active person.”It was 1993. Vrind was in her late 40s and working two jobs, athletics coach and a carer for disabled ...
Source: Healthy Living - The Huffington Post - May 30, 2015 Category: Consumer Health News Source Type: news

Cardiovascular Effects of Methotrexate in Rheumatoid Arthritis Revisited.
This article overviews some mechanisms of action of methotrexate on TRF, clinical and subclinical manifestations of RA-induced atherosclerosis, and related cardiovascular morbidity and mortality. PMID: 25876749 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - April 15, 2015 Category: Chemistry Authors: Popkova TV, Novikova DS, Gasparyan AY, Nasonov EL Tags: Curr Med Chem Source Type: research

Cardiovascular outcomes and systemic anti‐inflammatory drugs in patients with severe psoriasis: 5‐year follow‐up of a Danish nationwide cohort
ConclusionSystemic anti‐inflammatory treatment with methotrexate was associated with significantly lower rates of cardiovascular events during long‐term follow‐up compared to patients treated with other antipsoriatic therapies. The treatment strategy in patients with severe psoriasis may have an impact on cardiovascular outcomes and randomized trials to evaluate the cardiovascular safety and efficacy of systemic antipsoriatic therapies are called for.
Source: Journal of the European Academy of Dermatology and Venereology - October 10, 2014 Category: Dermatology Authors: O. Ahlehoff, L. Skov, G. Gislason, R. Gniadecki, L. Iversen, L.E. Bryld, S. Lasthein, J. Lindhardsen, S.L. Kristensen, C. Torp‐Pedersen, P.R. Hansen Tags: Original Article Source Type: research

Tumor Necrosis Factor α Inhibitor Use and Decreased Risk for Incident Coronary Events in Rheumatoid Arthritis
ConclusionUse of TNFα inhibitors is associated with a decreased risk for CAD in RA; the risk decreases further with long‐term use. This should be considered when weighing the risks versus benefits of these medications.
Source: Arthritis Care and Research - February 24, 2014 Category: Rheumatology Authors: Androniki Bili, Xiaoqin Tang, Shruthi Pranesh, Rasa Bozaite, Stephanie J. Morris, Jana L. Antohe, H. Lester Kirchner, Mary Chester M. Wasko Tags: Rheumatoid Arthritis Source Type: research

Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA)
Conclusions Among RA patients, there is a high prevalence of comorbidities and their risk factors. In this multinational sample, variability among countries was wide, not only in prevalence but also in compliance with recommendations for preventing and managing these comorbidities. Systematic measurement of vital signs and laboratory testing detects otherwise unrecognised comorbid conditions.
Source: Annals of the Rheumatic Diseases - December 4, 2013 Category: Rheumatology Authors: Dougados, M., Soubrier, M., Antunez, A., Balint, P., Balsa, A., Buch, M. H., Casado, G., Detert, J., El-zorkany, B., Emery, P., Hajjaj-Hassouni, N., Harigai, M., Luo, S.-F., Kurucz, R., Maciel, G., Mola, E. M., Montecucco, C. M., McInnes, I., Radner, H., Tags: Open access, Immunology (including allergy), Connective tissue disease, Degenerative joint disease, Musculoskeletal syndromes, Osteoporosis, Rheumatoid arthritis, Epidemiology, Calcium and bone Clinical and epidemiological research Source Type: research

TNF‐α inhibitor use and decreased risk for incident coronary events in rheumatoid arthritis patients
Conclusion: Use of TNF‐α inhibitors is associated with a decreased risk for CAD in RA; the risk decreases further with longterm use. This should be considered when weighing the risks versus benefits of these medications. © 2013 American College of Rheumatology.
Source: Arthritis Care and Research - September 10, 2013 Category: Rheumatology Authors: Androniki Bili, Xiaoqin Tang, Shruthi Pranesh, Rasa Bozaite, Stephanie J. Morris DO, Jana L. Antohe, H. Lester Kirchner, Mary Chester M. Wasko Tags: Original Article Source Type: research

Cardiovascular Risk in Rheumatoid Arthritis: Comparing TNF-α Blockade with Nonbiologic DMARDs
Conclusion: Among subjects with rheumatoid arthritis, TNF-α blocking agents may be associated with a reduced risk of cardiovascular events compared with an nbDMARD. Randomized controlled clinical trials should be considered to test this hypothesis.
Source: The American Journal of Medicine - July 26, 2013 Category: Journals (General) Authors: Daniel H. Solomon, Jeffrey R. Curtis, Kenneth G. Saag, Joyce Lii, Lang Chen, Leslie R. Harrold, Lisa J. Herrinton, David J. Graham, Mary K. Kowal, Bindee Kuriya, Liyan Liu, Marie R. Griffin, James D. Lewis, Jeremy A. Rassen Tags: Clinical research studies Source Type: research

Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review
Abstract Previous epidemiological studies have demonstrated a high prevalence of cardiovascular (CV) risk factors in psoriasis patients, including metabolic syndrome, cigarette smoking, obesity, hypertension, diabetes mellitus, insulin resistance and dyslipidaemia. An increase in CV morbidity and mortality attributable to psoriasis is still under question. Primary objective: to assess CV morbidity and mortality in psoriasis and psoriatic arthritis (PsA) including stroke, coronary artery disease, myocardial infarction (MI) and peripheral artery disease. Secondary objectives: to assess if psoriasis per se is an independent C...
Source: Journal of the European Academy of Dermatology and Venereology - July 11, 2013 Category: Dermatology Authors: C. Horreau, C. Pouplard, E. Brenaut, T. Barnetche, L. Misery, B. Cribier, D. Jullien, S. Aractingi, F. Aubin, P. Joly, M. Maître, J.‐P. Ortonne, C. Paul, M.‐A. Richard Tags: Review Article Source Type: research

Rationale and design of the Cardiovascular Inflammation Reduction Trial: A test of the inflammatory hypothesis of atherothrombosis
Background: Inflammation plays a fundamental role in atherothrombosis. Yet, whether direct inhibition of inflammation will reduce the occurrence of adverse cardiovascular outcomes is not known.Design: The Cardiovascular Inflammation Reduction Trial (CIRT) (ClinicalTrials.gov NCT01594333) will randomly allocate 7,000 patients with prior myocardial infarction (MI) and either type 2 diabetes or the metabolic syndrome to low-dose methotrexate (target dose 15-20 mg/wk) or placebo over an average follow-up period of 3 to 5 years. Low-dose methotrexate is a commonly used anti-inflammatory regimen for the treatment of rheumatoid a...
Source: American Heart Journal - May 6, 2013 Category: Cardiology Authors: Brendan M. Everett, Aruna D. Pradhan, Daniel H. Solomon, Nina Paynter, Jean MacFadyen, Elaine Zaharris, Milan Gupta, Michael Clearfield, Peter Libby, Ahmed A.K. Hasan, Robert J. Glynn, Paul M. Ridker Tags: Trial Design Source Type: research

Psoriasis Treatment Should Be Stratified in Order To Better Assess The Cardiovascular Event Rates
This article is protected by copyright. All rights reserved.
Source: Journal of Internal Medicine - April 20, 2013 Category: Internal Medicine Authors: Ilknur Balta, Sevket Balta, Mustafa Cakar, Sait Demirkol, Turgay Celik Tags: Letter to the Editor Source Type: research

Pages: 1  2